A recent study published in Nature Communications by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators evaluated a replicating RNA (repRNA) vaccine designed to target a contemporary bovine-derived H5N1 virus and compared its efficacy to a vaccine based on a historical H5N1 strain used in stockpiled vaccines.